Company intelligence / Profile preview

eTheRNA

Niel, Flanders, Belgiumetherna.be ↗

Ownership: Private
Employees: ~96
Development stage: Preclinical

Overview

eTheRNA has demonstrated the ability of its proprietary mRNA and LNP platforms to deliver targeted biodistribution and immune activation. Its lead programs are focused on cancer immunotherapy using dendritic cell-targeted approaches. The company’s TriMix platform has shown promise in boosting immune responses with a favorable safety profile. Some programs have advanced into clinical trials targeting solid tumors and infectious diseases, but detailed late-stage results are not publicly available as of June 2025.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA therapeuticsLipid Nanoparticles (LNPs)
Industry: Biotech

Partnerships

Notable partnerships with pharma/biotech companies for RNA therapeutics development; specific partners include Leaps by Bayer for inverse RNA vaccines research.

Beyond the preview

Go deeper on eTheRNA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eTheRNA.

Explore the full profile